Bisphosphonate

Phase 3Small molecule

Amgen

Bisphosphonate is one of 75 small molecule programs targeting Osteogenesis Imperfecta. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Osteogenesis ImperfectaActive, not recruiting

Breast CancerActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Osteogenesis ImperfectaPhase 3

Active, not recruiting

Breast CancerPreclinical

Active, not recruiting

Chronic Kidney DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Bisphosphonate

Amgen

Phase 3

2 3

Adriamycin

GGynecologic Oncology Group

Preclinical

87 4

Gemzar

GGynecologic Oncology Group

Preclinical

22 5

Megace

Bristol-Myers Squibb

Preclinical

4 6

Blenoxane

Bristol-Myers Squibb

Preclinical

1 7

Apatinib Mesylate

BBukwang Pharmaceutical

Preclinical

3 8

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

1 9

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Preclinical

1 10

Lipegfilgrastim

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Active, not recruiting

Osteogenesis Imperfecta

NCT05768854

Q3 2027

Phase 3Recruiting

Osteogenesis Imperfecta

NCT05972551

Post-ApprovalRecruiting

Caloric Restriction

NCT05764733

Clinical

Trials by Indication[1]

Osteogenesis Imperfecta2 trials

Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta

Recruiting· Amgen logo

Amgen·Phase 3·NCT05972551·106 enrolled

Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta

Active, not recruiting· Ultragenyx logo

Ultragenyx·Phase 3·NCT05768854·69 enrolled

Breast Cancer2 trials

Prospective Research for Elderly (≥65 Years Old) Early Breast Cancer Patients

Unknown status·PPeking Union Medical College Hospital··NCT05680194·1,000 enrolled

Breast Cancer Women on Aromatase Inhibitors Treatment

Unknown status·PParc de Salut Mar·Phase 4·NCT03811509·1,000 enrolled

ESS1 trial

Denosumab Safety Assessment in Multiple Observational Databases

Completed· Amgen logo

Amgen··NCT02520362·517,991 enrolled

Caloric Restriction1 trial

Bone, Exercise, Alendronate, and Caloric Restriction

Recruiting·WWake Forest University Health Sciences·Phase 4·NCT05764733·900 enrolled

Fractures1 trial

Exome Sequencing for Atypical Femoral Fractures

Completed·WWashington University School of Medicine··NCT02731040·38 enrolled

2 more indications

Chronic Kidney Disease1 trial

Queen's University Investigation of Calcification in Chronic Kidney Disease

Completed·QQueen's University·Phase 3·NCT00687661·25 enrolled

Unspecified1 trial

Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)

Completed· Pfizer logo

Pfizer··NCT01416194·10,497 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Bisphosphonate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bisphosphonate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bisphosphonate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Amgen

Bisphosphonate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Trials by Indication[1]

Osteogenesis Imperfecta2 trials

Breast Cancer2 trials

ESS1 trial

Caloric Restriction1 trial

Fractures1 trial

Chronic Kidney Disease1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News